A study examining the use of magic mushrooms in Canada revealed that nearly 80% of participants agreed that psilocybin should be provided as a medical treatment for distressed patients. Moreover, about two-thirds of the Canadian participants in the study supported the idea that psilocybin should be legally obtainable by those in need.
Alongside making psilocybin more accessible, an impressive 84.8 percent of participants asserted that the public health system should cover the expenses of such treatments. A considerable number of Canadians perceive psilocybin as a viable option, especially for treating distress related to end-of-life.
[toc]
Key Findings:
- Residents of Québec, Ontario, Alberta, and British Columbia acknowledge psilocybin as a legitimate medical option for managing end-of-life existential distress.
- Magic mushrooms are deemed safe for the treatment of existential distress.
- Participants in two double-blind trials experienced immediate and long-lasting benefits, with effects persisting for six months or even more.
Understanding Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals face their own mortality. Patients may encounter feelings of helplessness, isolation, anxiety, and a loss of purpose and meaning. This type of distress predominantly affects patients with life-threatening conditions, potentially leading to thoughts of hastening death or considering suicide.
Usually, individuals grappling with terminal diseases or significant life changes are the ones most likely to experience this type of distress. It severely impacts their mental health and overall life quality.
Existential therapy aims to address issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. This therapy may require multiple sessions and may not prove successful for all.
The uncertainty about the effectiveness of such therapy has led many individuals to explore alternative treatments.
The Stance of Health Canada on Psilocybin as a Therapeutic Option
In the past two decades, preliminary clinical trials have highlighted the possible therapeutic advantages of psychedelic substances for complex mental health conditions. Psilocybin, especially, has demonstrated quick and sustained relief for existential distress in patients nearing life’s end.
Recognizing the potential efficacy of these suggested hallucinogenic mushrooms, especially when traditional treatments are not effective, Health Canada updated the Special Access Program in 2022. This modification permits healthcare providers to request controlled substances for their patients.
Canadian Support for Access to Psilocybin
A study published in the Palliative Care Journal evaluates societal viewpoints on psilocybin-assisted therapy for end-of-life care. The study’s data comprises:
| Methodology | Engagement from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of these had previous experience with psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% regard psilocybin-assisted therapy as a legitimate medical option for treating end-of-life existential distress. 63.3% think psilocybin should be integrated into medical treatment. 84.8% advocate for the public health system providing this therapy. 44.2% believe healthcare professionals should administer the substance without Health Canada’s supervision. |
The findings align with surveys from Canada, England, and Australia. The researchers stressed that their study is distinct as it focuses on the use of psychoactive substances for treating existential distress in end-of-life situations.
Reasons Behind Canadian Support for Psilocybin Use
An increasing population of Canadians are endorsing the use of psilocybin as a treatment, primarily due to the conclusions of reputable research institutions. An additional influencing factor is the perceived safety of psilocybin mushrooms for mitigating existential distress. Subjects across multiple studies have not reported severe adverse health effects, such as multiple organ failure.
| Study | Approach | Outcomes |
| Johns Hopkins Study | 51 patients received a high dose of psilocybin and a low dose as an active placebo control | Immediate and enduring The benefits are lasting, extending up to six months or more. The effectiveness of the therapy is largely attributed to mystical experiences characterized by a sense of unity and profound emotional insights. |
| New York University Experiment | 29 patients were randomly assigned to receive either psilocybin or the active placebo niacin | The results of the experiment were in line with the Johns Hopkins study. Participants who were administered psilocybin reported psychological relief and an enhanced perspective on life and death. |
| BMC Palliative Care | Nineteen participants (consisting of 7 doctors, 4 active nurses, 4 chaplains, 3 social workers, and a psychologist) were interviewed. The aim of the study was to understand the perception of palliative care professionals towards existential distress and their view on psychedelic therapy as a treatment option. | As per the palliative care practitioners, psychedelic-assisted therapy (PAT) demonstrates potential in alleviating existential distress. |
Patient Experiences
Scientific studies aren’t the sole evidence supporting the effectiveness of psilocybin. Numerous patient narratives further emphasize its potential in enhancing mental wellbeing and overall quality of life.
Yokoi’s Experience
Mio Yokoi, who was suffering from terminal stage 4 pancreatic cancer, narrates an enlightening experience during her assisted therapy. She envisions herself on a raft, surrounded by nature, and accompanied by imaginative creatures. This vision evokes in her a profound realization of the universe’s interconnectedness and support, providing her immense peace and affirmation.
Despite availing traditional mental health support, Yokoi continued to suffer from severe anxiety and distress following her diagnosis. Psilocybin therapy aided her in reestablishing a connection with her body and provided a tangible sense of love and support. This has significantly improved her emotional and mental health.
Chrissy’s Narrative
Chrissy, a woman in her 50s, was battling stage 4 breast cancer that had metastasized to her lungs. She held a full-time role as an administrative supervisor in healthcare during the time of the study and identified herself as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy reported notable reductions in her levels of anxiety, depression, fear of death, hopelessness, and demoralization. When asked about any shifts in her religious or spiritual beliefs post her therapy session, she responded that the experiences had infused meaning and substance into her beliefs.
Brenda’s Journey
In her therapy sessions, Brenda experienced death twice. These experiences led to her no longer fearing death and seeing it instead as a beautiful part of life’s journey. She attributed her healing from childhood trauma to the study. Her data reflected this profound change.
Notable improvements included an alleviation of anxiety and death-related fears, coupled with an increase in spirituality.
Availability of Magic Mushroom Products in Canada
At present, the accessibility of psilocybin capsules and other products designed for existential distress or other mental health conditions may be limited. However, reliable online dispensaries can be a useful resource for these products when necessary.
| Feature | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and some adjacent South American nations. | Located in Cambodia, near the Angkor Wat Temple. | Related to the Penis Envy mushrooms, which rose to fame in the 1970s. |
| Potency | Moderately potent; recommended for beginners. | Moderately potent as well; suitable for those new to the experience. | Highly potent; suggested for those with more experience. |
| Effects | Causes a mental buzz, slight disorientation, enhanced color perception, euphoria, spiritual experiences, increased creativity, and improved focus. | Induces an energizing and sustained high, minor visual changes, increased creativity, euphoria, a gentle physical high, fractal imagery, and feelings of joy. | Produces intense shamanic experiences, vision quests, profound mystical experiences, elevated creativity, focus, social awareness, and mood enhancement. |
Mitigate End-of-life Distress with Psilocybin Products
Existential or end-of-life distress can impose a significant burden on patients nearing the end of their lives. Traditional treatments may not always provide sufficient relief, leading to an increase in Canadian advocacy for easier access to magic mushrooms in public healthcare. This burgeoning public interest could We advocate for regulatory authorities to recognize the potential of magic mushrooms as a viable therapeutic alternative. Acquire your psychedelics and mushroom delivery from Deadhead Chemist Canada.
Frequently Asked Questions
What should patients expect during Psilocybin-Assisted Therapy?
Psychedelic-assisted therapy (PAT) outcomes can greatly differ among patients, and meticulous preparation and adherence to specific procedures are crucial to ensure positive results. Patients must undergo thorough screening and mental readiness prior to ingesting the substance.
- Pre-Session Preparation: Patients undergo a detailed evaluation. The therapist and patient discuss the patient’s goals and expectations to set the session’s intentions. The therapist also elaborates on the process’s impact and what the patients should expect during the session.
- The Session: During the session, patients receive a controlled dosage of the substance in a serene, distraction-free environment to promote relaxation and introspection. The therapist provides continuous support and guidance throughout this process.
- Post-Session Integration Therapy: This therapy helps patients interpret and assimilate their experiences. Follow-up sessions provide continuous support and counselling to solidify the insights and transformations achieved during therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by binding to serotonin receptors, particularly the 5-HT2A receptor. This interaction can alter perception, mood, and cognition, leading to significant shifts in consciousness, emotional breakthroughs, and new viewpoints.
Is psilocybin therapy available to everyone?
Psilocybin therapy isn’t universally suitable. Patients with particular mental health conditions or existential distress undergo rigorous screening to rule out those with a history of psychosis.
Related Articles:
